For neoadjuvant platinum in triple negative cancer, for capecitabine, in HER2 negative residual cancer after neoadjuvant chemotherapy, and for neratinib in HER2 positive cancer, no trials reported breast cancer mortality. The gene discussed is ERBB2; the disease is breast carcinoma.